Login to Your Account

Third Acquisition in Eight Months

Gilead Continues to Diversify with $600M Calistoga Deal

By Tom Wall

Wednesday, February 23, 2011
Gilead Sciences Inc. made its third major acquisition in the past eight months, buying privately held Calistoga Pharmaceuticals Inc., of Seattle, for $375 million cash and $225 million in potential milestones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription